Evidence map›Paper›PMID 34234192›Full record

ArticleScientific reports2021

Author Correction: The randomized ZIPANGU trial of ranibizumab and adjunct laser for macular edema following branch retinal vein occlusion in treatment‑naïve patients.

Toshinori Murata, Mineo Kondo, Makoto Inoue, Shintaro Nakao, Rie Osaka, Chieko Shiragami, Kenji Sogawa, Akikazu Mochizuki, Rumiko Shiraga, Yohei Ohashi and 4 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Toshinori MurataDepartment of Ophthalmology, Shinshu University School of Medicine, 3‑1‑1 Asahi, Matsumoto, Nagano, Japan. murata@shinshu-u.ac.jp.
Mineo KondoDepartment of Ophthalmology, Mie University Graduate School of Medicine, Mie, Japan.
Makoto InoueDepartment of Ophthalmology, Kyorin Eye Center, Kyorin University School of Medicine, Tokyo, Japan.
Shintaro NakaoDepartment of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Rie OsakaDepartment of Ophthalmology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Chieko ShiragamiDepartment of Ophthalmology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Kenji SogawaDepartment of Ophthalmology, Asahikawa Medical University, Hokkaido, Japan.
Akikazu MochizukiNovartis Pharma K.K., Tokyo, Japan.
Rumiko ShiragaNovartis Pharma K.K., Tokyo, Japan.
Yohei OhashiNovartis Pharma K.K., Tokyo, Japan.
Takeumi KanekoNovartis Pharma K.K., Tokyo, Japan.
Chikatapu ChandrasekharNovartis Healthcare Pvt. Ltd., Hyderabad, India.
Akitaka TsujikawaDepartment of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Motohiro KameiDepartment of Ophthalmology, Aichi Medical University, Aichi, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID34234192
PMCPMC8263590

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.